Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02FXU
|
||||
| Former ID |
DCL000147
|
||||
| Drug Name |
Lapaquistat acetate
|
||||
| Synonyms |
Lapaquistat acetate (USAN); TAK-475; 1-((1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hyperlipidaemia [ICD9: 272.0-272.4; ICD10:E78] | Discontinued in Phase 3 | [522119] | ||
| Company |
Takeda Chemical Industries
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C33H41ClN2O9
|
||||
| Canonical SMILES |
CC(=O)OCC(C)(C)CN1C2=C(C=C(C=C2)Cl)C(OC(C1=O)CC(=O)N3CC<br />C(CC3)CC(=O)O)C4=C(C(=CC=C4)OC)OC
|
||||
| InChI |
1S/C33H41ClN2O9/c1-20(37)44-19-33(2,3)18-36-25-10-9-22(34)16-24(25)30(23-7-6-8-26(42-4)31(23)43-5)45-27(32(36)41)17-28(38)35-13-11-21(12-14-35)15-29(39)40/h6-10,16,21,27,30H,11-15,17-19H2,1-5H3,(H,39,40)/t27-,30-/m1/s1
|
||||
| InChIKey |
CMLUGNQVANVZHY-POURPWNDSA-N
|
||||
| CAS Number |
CAS 189060-13-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Squalene synthetase | Target Info | Inhibitor | [536444], [536754] | |
| PANTHER Pathway | Cholesterol biosynthesis | ||||
| PathWhiz Pathway | Steroid Biosynthesis | ||||
| References | |||||
| Ref 536444 | Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol Appl Pharmacol. 2007 Aug 15;223(1):39-45. Epub 2007 May 24. | ||||
| Ref 536754 | Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. Br J Pharmacol. 2008 Jul;154(5):949-57. Epub2008 Apr 21. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.